GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (WAR:MAB) » Definitions » Price-to-Owner-Earnings

Mabion (WAR:MAB) Price-to-Owner-Earnings : 10.22 (As of Jan. 18, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Mabion Price-to-Owner-Earnings?

As of today (2025-01-18), Mabion's share price is zł9.40. Mabion's Owner Earnings per Share (TTM) ended in Sep. 2024 was zł0.92. It's Price-to-Owner-Earnings for today is 10.22.


The historical rank and industry rank for Mabion's Price-to-Owner-Earnings or its related term are showing as below:

WAR:MAB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.86   Med: 8.37   Max: 17.9
Current: 10.92

During the past 13 years, the highest Price-to-Owner-Earnings of Mabion was 17.90. The lowest was 3.86. And the median was 8.37.


WAR:MAB's Price-to-Owner-Earnings is ranked better than
88.24% of 119 companies
in the Biotechnology industry
Industry Median: 29.67 vs WAR:MAB: 10.92

As of today (2025-01-18), Mabion's share price is zł9.40. Mabion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was zł0.61. Therefore, Mabion's PE Ratio (TTM) for today is 15.41.

As of today (2025-01-18), Mabion's share price is zł9.40. Mabion's EPS without NRI for the trailing twelve months (TTM) ended in was zł1.33. Therefore, Mabion's PE Ratio without NRI for today is 7.08.

During the past 13 years, Mabion's highest PE Ratio without NRI was 500.86. The lowest was 4.78. And the median was 7.55.


Mabion Price-to-Owner-Earnings Historical Data

The historical data trend for Mabion's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabion Price-to-Owner-Earnings Chart

Mabion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 12.73 -

Mabion Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.85 - - 12.17 18.12

Competitive Comparison of Mabion's Price-to-Owner-Earnings

For the Biotechnology subindustry, Mabion's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mabion's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabion's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Mabion's Price-to-Owner-Earnings falls into.



Mabion Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Mabion's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=9.40/0.92
=10.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mabion  (WAR:MAB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Mabion Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Mabion's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Mabion Business Description

Industry
Traded in Other Exchanges
Address
ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.

Mabion Headlines